Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel
Akhtar O, Hashmi H, Oloyede T, Brazauskas R, Bye M, Sidana S, Hansen D, Ahmed N, Ferreri C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Harrison M, Kitali A, Landau H, Mirza A, Patel J, Patwardhan P, Qazilbash M, Patel K, Nishihori T, Ganguly S, Pasquini M, Usmani S, Freeman C. Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel. Transplantation And Cellular Therapy 2024, 30: s184-s185. DOI: 10.1016/j.jtct.2023.12.239.Peer-Reviewed Original ResearchCytokine-release syndromeProgression-free survivalTreatment-related mortalityClinically significant infectionsRelapse/refractory multiple myelomaOverall survivalIde-celProlonged cytopeniasMultiple myelomaBaseline characteristicsAnti-BCMA CAR-T cell therapyHematopoietic cell transplant-specific comorbidity indexFrail patientsComorbidity indexHigh-grade adverse eventsCAR-T cell therapyRates of overall responseNon-frail patientsRate of neurotoxicityClinically important subgroupsCharlson Comorbidity IndexAge cut-offAnti-BCMAHCT-CIComplete response